The Low DoseThe GLP-1 price desk
Programme

Ro tirzepatide review

Advertised at $149, billed at $448. Position 17 of 18 on our board.

Updated 2026-09-18

DISCLOSURE — Coreage Rx pays this desk a commission when a reader signs up through our link. It buys no ranking, no score and no deletions. Method: how we rate. Full terms: disclosure.

Ro is the only listing on our board that walked away from compounded GLP-1s entirely. It now works with FDA-approved medication only.

That is a real editorial decision on their part, and it costs their customers real money. The Ro Body membership is $149 a month and contains no medication. Branded Zepbound is billed on top at roughly $299 to $499 a month through manufacturer self-pay channels.

The numbers

Ro · tirzepatide
Advertised$149/mo
Membership$149/mo
Billed$448/mo
Advertised-to-billed gap+$299/mo
Per year$5,376
Board position17 of 18, cheapest first

Membership only. Branded Zepbound is billed on top, typically $299-$499/month through manufacturer self-pay channels.

Where the gap is

The gap here is not a hidden fee — Ro is clear that medication is separate. The gap is between what people assume a $39 first month buys and what it actually buys, which is one month of membership and no drug at all.

Against the board

Around $5,376 a year for a cash payer, the dearest route on the board. With insurance coverage it can be the cheapest. Nothing else on this board swings that far on one variable.

ProgrammeAdvertisedBilledGapVs board floor
Coreage Rx$149$199+$50+$74/mo
Trimi$125$125none
Ozari Health$125$125none
Fifty 410$133$133none+$8/mo
PlexusDx$129$189+$60+$64/mo
Ivím Health$199$199none+$74/mo
Zealthy$216$216none+$91/mo
Hims & Hers$199$238+$39+$113/mo

How the programme works

Membership-first telehealth service. Ro exited compounded GLP-1s and now routes patients to FDA-approved branded medication, billed separately from the membership.

Verified facts

  • Ro Body membership is $39 for the first month, then $149/month.
  • Membership does not include the cost of GLP-1 medication.
  • Ro has exited compounded GLP-1s and works with FDA-approved branded products.
  • Effective all-in cost commonly lands between $298 and $598/month depending on the medication and any insurance coverage.
  • Cancellation requires notice before the renewal date.

Checked 2026-09-18. This market re-prices without notice — anything older than a month is a starting point, not a quote.

For it

  • FDA-approved medication only, which removes the compounding-regulation question entirely.
  • Genuine help pursuing insurance coverage.
  • Clear that medication is not included in the membership.

Against it

  • The $149/month membership buys no medication at all.
  • Total cost is among the highest here for anyone paying cash.
  • No compounded option for people who cannot afford branded pricing.

Read this bit. The membership and the medication are two separate bills. A $39 first month does not mean a $39 prescription.

Score

3.5 out of 5 on our rubric, which is fixed before assessment and published on how we rate.

CriterionWeightScore
True monthly cost30%2.4 / 5
Price honesty20%3.8 / 5
Clinical support20%4.1 / 5
Pharmacy sourcing15%4.8 / 5
Cancelling15%3.4 / 5

Verdict

Check your formulary before you look at anything else. Covered, Ro is a sound conservative pick. Uncovered, it is the most expensive line we track.

More from the desk

  • Coreage Rx tirzepatide review

    Advertised at $149, billed at $199. Position 1 of 18 on our board.

  • Trimi tirzepatide review

    Advertised at $125 and billed at $125 — no gap. Position 2 of 18 on our board.

  • Ozari Health tirzepatide review

    Advertised at $125 and billed at $125 — no gap. Position 3 of 18 on our board.

  • Cheapest right now

    Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.

  • Six fee traps

    Every advertised-to-billed gap on our board comes from one of these six structures. Learn them and you can read any of these sites in ninety seconds.

  • Where the traps are

    The biggest advertised-to-billed gaps on our board, and the programmes charging most for the same category of medication.